Market Introduction
Liposomes are small sphere-shaped artificial vesicles synthesized from cholesterol and phospholipids. They have multiple layers and a diameter range of 0.01 to 5.0 um. They also have hydrophilic and hydrophobic properties which help liposomes to encapsulate hydrophobic and hydrophilic drugs to be delivered to targeted body site. Liposomes provide an assured system for targeted drug delivery and thereby is the factor influencing the Liposome Drug Delivery market size growth. Liposomes are widely used for enclosing all types of drug molecules such as acyclovir, chloroquine diphosphate, paclitaxel, tropicamide, and cyclosporine. Liposomes are used as a drug carrier for drug therapy for many diseases since they are biodegradable and biocompatible. Also, they have many therapeutic properties like anticancer drugs, genetic materials, proteins, vaccines, macromolecules, and thus can be encapsulated in liposomes.
Market Overview and Dynamics
The Asia Pacific liposome drug delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019. The market is estimated to grow with a CAGR of 9.6% from 2020-2027. The growth of the market is attributed to the some key driving factors such as high incidence of chronic diseases amongst the population, an upsurge in need for non-invasive drug delivery solutions, increasing investments in R&D for pharmaceutical companies. However, high expense involved in the development of drug delivery systems is expected to obstruct the growth of the market to a certain extent during the forecast years
Key Market Segments
In terms of product, the liposomal doxorubicin is expected to hold the largest share of the liposome drug delivery market by 2027. In terms of technology, the stealth liposome technology held the most significant market share of the liposome drug delivery market. In terms of the application, the cancer therapy segment is expected to maintain its largest market share by 2027.
Major Sources and Companies Listed
Some of the major primary and secondary sources for liposome drug delivery market included in the report are National Cancer Institute (NCI), Chinese Society of Clinical Oncology (CSCO) Guidelines, and others.
.Reasons to buy the report
ASIA PACIFIC LIPOSOME DRUG DELIVERY MARKET SEGMENTATION
By Product
By Technology
By Application
Companies Mentioned-
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 759.81 Million |
| Market Size by 2027 | US$ 1,562.92 Million |
| CAGR (2020 - 2027) | 9.6% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Liposome Drug Delivery Market is valued at US$ 759.81 Million in 2019, it is projected to reach US$ 1,562.92 Million by 2027.
As per our report Asia Pacific Liposome Drug Delivery Market, the market size is valued at US$ 759.81 Million in 2019, projecting it to reach US$ 1,562.92 Million by 2027. This translates to a CAGR of approximately 9.6% during the forecast period.
The Asia Pacific Liposome Drug Delivery Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Liposome Drug Delivery Market report:
The Asia Pacific Liposome Drug Delivery Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Liposome Drug Delivery Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Liposome Drug Delivery Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Liposome Drug Delivery Market
